DCTH vs INCY: fair value comparison
Delcath Systems, Inc. and Incyte Corporation · Updated 2026-10-19
DCTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DCTH currently ranks higher by quality score.
| DCTH | INCY | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $14.08 | $112.79 |
| 12-month range | $8.19–$17.36 | $89.31–$129.93 |
| Rank by discount to fair value | — | #23 of 108 Healthcare |
| Rank by quality score | #2 of 301 Healthcare | #3 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: DCTH fair value analysis · INCY fair value analysis